Vertex Pharmaceuticals Inc (VRTX)
491.89
+18.58
(+3.93%)
USD |
NASDAQ |
Nov 05, 10:20
Vertex Pharmaceuticals Cash from Operations (Quarterly): -3.754B for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -3.754B |
| March 31, 2024 | 1.307B |
| December 31, 2023 | 234.60M |
| September 30, 2023 | 1.268B |
| June 30, 2023 | 1.134B |
| March 31, 2023 | 899.90M |
| December 31, 2022 | 1.078B |
| September 30, 2022 | 955.50M |
| June 30, 2022 | 1.140B |
| March 31, 2022 | 956.20M |
| December 31, 2021 | 995.00M |
| September 30, 2021 | 927.20M |
| June 30, 2021 | -199.70M |
| March 31, 2021 | 921.00M |
| December 31, 2020 | 491.53M |
| September 30, 2020 | 907.75M |
| June 30, 2020 | 1.039B |
| March 31, 2020 | 815.70M |
| December 31, 2019 | 445.98M |
| September 30, 2019 | 334.79M |
| June 30, 2019 | 463.75M |
| March 31, 2019 | 324.78M |
| December 31, 2018 | 314.58M |
| September 30, 2018 | 381.35M |
| June 30, 2018 | 321.70M |
| Date | Value |
|---|---|
| March 31, 2018 | 252.66M |
| December 31, 2017 | 227.51M |
| September 30, 2017 | 170.09M |
| June 30, 2017 | 181.65M |
| March 31, 2017 | 265.69M |
| December 31, 2016 | 144.72M |
| September 30, 2016 | 65.66M |
| June 30, 2016 | 40.86M |
| March 31, 2016 | -15.14M |
| December 31, 2015 | 29.14M |
| September 30, 2015 | -62.07M |
| June 30, 2015 | -110.27M |
| March 31, 2015 | -222.24M |
| December 31, 2014 | -181.78M |
| September 30, 2014 | -87.65M |
| June 30, 2014 | -127.92M |
| March 31, 2014 | -175.76M |
| December 31, 2013 | 19.76M |
| September 30, 2013 | -13.72M |
| June 30, 2013 | -0.927M |
| March 31, 2013 | -65.78M |
| December 31, 2012 | 40.56M |
| September 30, 2012 | 105.96M |
| June 30, 2012 | 118.40M |
| March 31, 2012 | 2.916M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-3.754B
Minimum
Jun 2024
1.307B
Maximum
Mar 2024
608.59M
Average
927.20M
Median
Sep 2021
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | 3.712B |
| Bristol-Myers Squibb Co | 5.591B |
| Regeneron Pharmaceuticals Inc | 1.291B |
| Sarepta Therapeutics Inc | 14.94M |
| Moderna Inc | -1.274B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -463.70M |
| Cash from Financing (Quarterly) | -358.60M |
| Free Cash Flow | -1.426B |
| Free Cash Flow Per Share (Quarterly) | -14.84 |
| Free Cash Flow to Equity (Quarterly) | -3.830B |
| Free Cash Flow to Firm (Quarterly) | -3.830B |
| Free Cash Flow Yield | -1.11% |